PD-1 and PD-L1 inhibitors are monoclonal antibodies that block certain immune system checkpoints, known as programmed cell death protein 1 (PD-1) and programmed death-ligand 1 (PD-L1). These drugs help the body’s immune system fight against cancer by removing brakes on the immune system called checkpoints. PD-1 and PD-L1 inhibitors are primarily used for treating various types of cancer like melanoma, lung cancer, kidney cancer, bladder cancer, head and neck cancer, Hodgkin’s lymphoma, and Merkel cell carcinoma.
The global PD-1 and PD-L1 inhibitor market is estimated to be valued at US$ 39.83 Bn in 2023 and is expected to exhibit a CAGR of 7.8% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Dynamics:
The global PD-1 and PD-L1 inhibitor market is expected to be flourished by growth in immuno-oncology therapies. Immuno-oncology is a form of cancer treatment that uses the body’s immune system to fight cancer. It involves drugs like PD-1 and PD-L1 inhibitors that can unleash the immune system on tumors. Approval and introduction of new PD-1 and PD-L1 inhibitor drugs and combination therapies is expected to drive the market growth during the forecast period. For instance, in June 2022, the FDA approved Keytruda (pembrolizumab), developed by Merck for adjuvant treatment of renal cell carcinoma. Also, ongoing clinical trials evaluating PD-1 and PD-L1 inhibitors for new cancer indications is anticipated to create lucrative opportunities. However, high cost associated with PD-1 and PD-L1 inhibitor drugs may hamper the market growth.
Segment Analysis
The PD-1 and PD-L1 inhibitor market is dominated by the oncology segment which accounts for more than 90% of the total market share. PD-1 and PD-L1 inhibitors are primarily used for the treatment of various cancers like melanoma, lung cancer, renal cancer, head and neck cancer, Hodgkin’s lymphoma, among others. Among these application segments, melanoma indication has been the largest revenue generating segment historically. However, non-small cell lung cancer (NSCLC) indication is expected to take the leading position in terms of market size during the forecast period owing to rising incidence of lung cancer cases globally.
PEST Analysis
Political: Government regulations around drug approval processes can impact the market growth. Strategic collaborations between pharmaceutical companies and academic research institutes are encouraging innovation.
Economic: Rising healthcare expenditure, increasing disposable income, growing demand for advanced cancer treatment options are fueling the market growth. High R&D costs associated with drug development can restrain the market.
Social: Growing public health awareness regarding new immunotherapies is positively impacting the adoption. However, affordability and access to expensive precision medications remain a challenge in developing regions.
Technological: Rapid advances in genomics and cancer immunotherapy research have led to development of novel PD-1 and PD-L1 inhibitors with improved efficacy and safety profiles. Combination therapies with CTLA-4 inhibitors are demonstrating encouraging results in clinical trials.
Key Takeaways
The Global PD-1 and PD-L1 Inhibitor Market Size is expected to witness high growth at a CAGR of 7.8% during the forecast period of 2023 to 2030. The market size is estimated to reach US$ 39.83 Bn by 2023.
Regional analysis: North America dominated the global market and is expected to maintain its leading position during the forecast period as well. The region accounted for over 50% of the total market share in 2023 owing to rising cancer incidence, availability of advanced treatment options and robust research infrastructure in the US and Canada.
Key players analysis: Key players operating in the PD-1 and PD-L1 inhibitor market are Sesajal S.A. de C.V., Olivado, Grupo Industrial Batellero S.A. de C.V, YASIN, Tron Hermanos SA de CV, The Village Press, Bella Vado, Chosen Foods LLC, and Storino’s Quality Products. Sesajal S.A. de C.V. captured the leading market share in 2023 owing to its comprehensive product portfolio and global commercial footprint.
